Clinical Publications
The Impact of EndoBarrier Gastrointestinal Liner in Obese Patients with Normal Glucose Tolerance and in Patients with Type 2 Diabetes
The duodenal-jejunal bypass sleeve ((DJBS) or EndoBarrier Gastrointestinal Liner) induces weight loss in obese subjects and may improve glucose homeostasis in patients with type 2 diabetes (T2D). To explore the underlying mechanisms, we evaluated postprandial physiology including glucose...
EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography.
Many obese people with type 2 diabetes develop non-alcoholic fatty liver disease, which may progress to liver fibrosis. EndoBarrier gastrointestinal liner is an innovative interventional treatment option for type 2 diabetic patients, which could affect diabetes associated liver disease.
Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
The duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the current study was to determine its efficacy and safety profile.
Safety- and efficacy-outcomes of the duodenal-jejunal bypass liner (DJBL) registry in obese patients with type 2 diabetes
Safety- and efficacy-outcomes of the duodenal-jejunal bypass liner (DJBL) registry in obese patients with type 2 diabetes
Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.
Implantation of a duodenal-jejunal endoluminal bypass liner (DJBL) has shown to induce weight loss and to improve metabolic parameters. DJBL is a reversible endoduodenal sleeve mimicking duodenal bypass while lacking risks and limitations of bariatric surgery. Effects on metabolic control, body...
Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier®) on Gastric Emptying in Obese and Type 2 Diabetic Patients
The duodenal-jejunal bypass liner (DJBL) is a promising technique for treating obesity and type 2 diabetes mellitus (T2DM). However, despite promising results, its mechanism of action has not been elucidated. It is thought to promote changes in gastric emptying owing to the neuro-endocrine...
ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.
The increasing global burden of obesity and its associated comorbidities has created an urgent need for additional treatment options to fight this pandemic. Endoscopic bariatric therapies (EBTs) provide an effective and minimally invasive treatment approach to obesity that would increase treatment...
Safety Experience with the Duodenal-Jejunal Bypass Liner: An Endoscopic Treatment for Diabetes and Obesity
The duodenal-jejunal bypass liner (DJBL) is a new, device-based endoscopic treatment for type 2 diabetes mellitus (T2DM) and obesity.
Statement from the German Diabetic Association (DDG) on the Termination of the “ENDO Trial” Study (FDA Study of the EndoBarrier in Patients with Type 2 Diabetes Mellitus)
On July 30, 2015, GI Dynamics (GID) announced that the clinical study (“Endo Trial”) conducted in the USA would be terminated with immediate effect.
The Effect of the Endoscopic Duodenal-Jejunal Bypass Liner on Obesity and Type 2 Diabetes Mellitus, A Multicenter Randomized Controlled Trial
Investigate the safety and efficacy of 6 months’ duodenal-jejunal bypass liner (DJBL) treatment in comparison with dietary intervention for obesity and type 2 diabetes mellitus (T2DM).
